Robert Browning (7 May 1812 – 12 December 1889), English poet and playwright.
It is with great sorrow that we and the IABS family learned of the death of Mrs. Claude Lardy on November 22.
We all owe a debt of gratitude to Claude Lardy. She was the inspiring force for all who devoted their lives to human and animal well-being. Her energy, perspicacity, capacity to listen, and humanitarian vision generated the energy that drove so many to save lives of humans and animals through access to vaccines everywhere.
IABS is so very grateful- to Claude for her non-ending support to Dr. Charles Mérieux, the initiator of IABS, and for her loyalty to the Alliance.
As IABS goes forward, we will do our best to apply Claude’s moto: « Talk with each other, Exchange your ideas, Respect one another , and Strive for consensus in order to create a better world ».
President of IABS
VAV2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the "Consistency Approach" for quality control of established vaccines, where current quality control approaches are often relying on in vivo methods.
VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with official medicines control laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physico-chemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the "Consistency Approach" for established vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.
About ZAPI - The new Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases…
Founding Members :